PBSV · Pharma-Bio Serv, Inc.
4 customers — 55.8% of revenue (the nine months ended July 31, 2026)
“During the nine months ended July 31, 2026, aggregate revenues from these global group of affiliated companies were 18.6%, 17.9%, 13.8% and 5.5%, or a total of 55.8%”
4 customers — 53.6% of revenue (the three months ended July 31, 2026)
“During the three months ended July 31, 2026, aggregate revenues from these global groups of affiliated companies were 23.8%, 22.8%, 6.4% and 0.6%, or a total of 53.6%”
4 customers — 52.6% of revenue (the nine months ended July 31, 2026)
“During the nine months ended July 31, 2026, revenues from these customers were 18.6%, 14.7%, 13.8% and 5.5%, or a total of 52.6%”
4 customers — 49.1% of revenue (the three months ended July 31, 2026)
“During the three months ended July 31, 2026, revenues from these customers were 23.8%, 18.3%, 6.4% and 0.6%, or a total of 49.1%”
One customer — 23.8% of revenue (the three months ended July 31, 2026)
“During the three months ended July 31, 2026, revenues from these customers were 23.8%, 18.3%, 6.4% and 0.6%, or a total of 49.1%”
One customer — 23.8% of revenue (the three months ended July 31, 2026)
“During the three months ended July 31, 2026, aggregate revenues from these global groups of affiliated companies were 23.8%, 22.8%, 6.4% and 0.6%, or a total of 53.6%”
One customer — 22.8% of revenue (the three months ended July 31, 2026)
“During the three months ended July 31, 2026, aggregate revenues from these global groups of affiliated companies were 23.8%, 22.8%, 6.4% and 0.6%, or a total of 53.6%”
One customer — 18.6% of revenue (the nine months ended July 31, 2026)
“During the nine months ended July 31, 2026, revenues from these customers were 18.6%, 14.7%, 13.8% and 5.5%, or a total of 52.6%”
One customer — 18.6% of revenue (the nine months ended July 31, 2026)
“During the nine months ended July 31, 2026, aggregate revenues from these global group of affiliated companies were 18.6%, 17.9%, 13.8% and 5.5%, or a total of 55.8%”
One customer — 18.3% of revenue (the three months ended July 31, 2026)
“During the three months ended July 31, 2026, revenues from these customers were 23.8%, 18.3%, 6.4% and 0.6%, or a total of 49.1%”
One customer — 17.9% of revenue (the nine months ended July 31, 2026)
“During the nine months ended July 31, 2026, aggregate revenues from these global group of affiliated companies were 18.6%, 17.9%, 13.8% and 5.5%, or a total of 55.8%”
One customer — 14.7% of revenue (the nine months ended July 31, 2026)
“During the nine months ended July 31, 2026, revenues from these customers were 18.6%, 14.7%, 13.8% and 5.5%, or a total of 52.6%”
One customer — 13.8% of revenue (the nine months ended July 31, 2026)
“During the nine months ended July 31, 2026, revenues from these customers were 18.6%, 14.7%, 13.8% and 5.5%, or a total of 52.6%”
One customer — 13.8% of revenue (the nine months ended July 31, 2026)
“During the nine months ended July 31, 2026, aggregate revenues from these global group of affiliated companies were 18.6%, 17.9%, 13.8% and 5.5%, or a total of 55.8%”
One customer — 6.4% of revenue (the three months ended July 31, 2026)
“During the three months ended July 31, 2026, aggregate revenues from these global groups of affiliated companies were 23.8%, 22.8%, 6.4% and 0.6%, or a total of 53.6%”
One customer — 6.4% of revenue (the three months ended July 31, 2026)
“During the three months ended July 31, 2026, revenues from these customers were 23.8%, 18.3%, 6.4% and 0.6%, or a total of 49.1%”
One customer — 5.5% of revenue (the nine months ended July 31, 2026)
“During the nine months ended July 31, 2026, aggregate revenues from these global group of affiliated companies were 18.6%, 17.9%, 13.8% and 5.5%, or a total of 55.8%”
One customer — 5.5% of revenue (the nine months ended July 31, 2026)
“During the nine months ended July 31, 2026, revenues from these customers were 18.6%, 14.7%, 13.8% and 5.5%, or a total of 52.6%”
One customer — 0.6% of revenue (the three months ended July 31, 2026)
“During the three months ended July 31, 2026, aggregate revenues from these global groups of affiliated companies were 23.8%, 22.8%, 6.4% and 0.6%, or a total of 53.6%”
One customer — 0.6% of revenue (the three months ended July 31, 2026)
“During the three months ended July 31, 2026, revenues from these customers were 23.8%, 18.3%, 6.4% and 0.6%, or a total of 49.1%”
4 customers — 44.5% of receivables (July 31, 2026)
“On July 31, 2026, amounts due from these customers represented 44.5% of the Company's total accounts receivable balance.”
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PBSV
this stock
Pharma-Bio Serv, Inc.
|
$10.99M | -20.0% | -5.3% | — | 0.0% |
|
VEEV
Veeva Systems Inc
|
$51.57B | +42.8% | +28.1% | 52.1 | 3.0% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$12.77B | -26.4% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$12.35B | +66.7% | +28.2% | 37.8 | 6.1% |
|
TEM
Tempus AI, Inc.
|
$11.61B | +13.0% | +83.4% | — | 13.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PBSV | +4.4% | +14.3% | -20.0% | +6.7% | -20.0% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | +5.8% | +15.2% | -27.7% | +6.2% | -32.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.